Related Experiment Video
Updated: Aug 4, 2026
09:54
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence
J C Schwartz1, J Diaz, R Bordet
1Unité de Neurobiologie et Pharmacologie (U.109) de l'INSERM, Centre Paul Broca, 2ter rue d'Alésia, 75014 Paris, France. schwartz@broca.inserm.fr
Brain Research. Brain Research Reviews
|July 4, 1998
Summary
Dopamine D1 and D3 receptors interact in complex ways, sometimes opposing and sometimes synergizing, influencing brain functions and potentially contributing to disorders like schizophrenia.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- The D3 dopamine receptor is selectively expressed in specific brain regions, including the ventral striatum.
- D3 receptors are found in medium-sized substance P neurons that also co-express D1 receptors.
- Interactions between D1 and D3 dopamine receptors are crucial for understanding striatal function.
Purpose of the Study:
- To investigate the interaction between D1 and D3 dopamine receptors in the brain.
- To elucidate the functional consequences of D1/D3 receptor co-expression and stimulation.
- To explore the role of D1/D3 receptor balance in neurological disorders.
Main Methods:
- Treatment of rats with selective D1 and D3 receptor agonists and antagonists.
- Measurement of c-fos expression and preprotachykinin mRNA levels in specific brain regions.
- Analysis of levodopa-induced behavioral sensitization in hemiparkinsonian rats.
Main Results:
- D1 and D3 receptors showed opposing effects on c-fos expression but synergistic effects on preprotachykinin mRNA enhancement in vivo.
- Repeated levodopa administration led to ectopic D3 receptor appearance in dorsal striatum, linked to D1 receptor stimulation and behavioral sensitization.
- Developmental processes may involve similar D1/D3 receptor interactions in the ventral striatum.
Conclusions:
- D1 and D3 dopamine receptors can mediate opposing or synergistic effects depending on the cellular context and signaling pathways.
- D1/D3 receptor interactions play a role in behavioral sensitization and may be relevant to brain development.
- Imbalances in neuronal D1 and D3 receptor levels are postulated to contribute to schizophrenic disorders.
Related Concept Videos
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:30Spare Receptors
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...